However, this case of chemorefractory extranodal natural-killer/T-cell lymphoma, nasal type, responded well to the novel drug pembrolizumab, which was able to control the disease. This evidence concerns the gene TNFRSF10B and T-cell non-Hodgkin lymphoma.